Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand.
Drugs. 2020 Mar;80(4):417-423. doi: 10.1007/s40265-020-01271-6.
Lumateperone (Caplyta) is a novel, orally available agent developed by Intra-Cellular Therapies (under a license from Bristol-Myers Squibb) for the treatment of schizophrenia and other neuropsychiatric and neurological disorders. Lumateperone is a first-in-class selective and simultaneous modulator of serotonin, dopamine and glutamate. In December 2019, lumateperone received its first global approval in the USA for the treatment of schizophrenia in adults. The drug is also under clinical development for bipolar depression, behavioural disorders associated with dementia and Alzheimer's disease, sleep maintenance insomnia and major depressive disorders. This article summarizes the milestones in the development of lumateperone leading to this first approval for the treatment of schizophrenia.
鲁马替培酮（Caplyta）是一种新型、口服制剂，由 Intra-Cellular Therapies（从 Bristol-Myers Squibb 获得授权）研发，用于治疗精神分裂症和其他神经精神及神经疾病。鲁马替培酮是一种首创的、选择性的、同时调节 5-羟色胺、多巴胺和谷氨酸的药物。2019 年 12 月，鲁马替培酮在美国获得了首个全球批准，用于治疗成人精神分裂症。该药物也正在开发用于双相情感障碍、与痴呆和阿尔茨海默病相关的行为障碍、睡眠维持性失眠和重度抑郁症。本文总结了鲁马替培酮的开发历程中的重要里程碑，最终该药获得批准，用于治疗精神分裂症。
